Orgenesis Stock Today
| ORGS Stock | USD 0.60 0.45 300.00% |
PerformanceSolid
| Odds Of DistressHigh
|
Orgenesis is selling for under 0.6 as of the 28th of January 2026; that is 300.00 percent increase since the beginning of the trading day. The stock's lowest day price was 0.16. Orgenesis has more than 64 % chance of experiencing financial distress in the next few years of operation. However, it had a very solid returns during the last 90 days. The performance scores are derived for the period starting the 30th of October 2025 and ending today, the 28th of January 2026. Click here to learn more.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 4.77 M outstanding shares of which 56.25 K shares are now shorted by private and institutional investors with about 2.39 trading days to cover. More on Orgenesis
Moving against Orgenesis Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Orgenesis Pink Sheet Highlights
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Orgenesis [ORGS] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.07 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Orgenesis's market, we take the total number of its shares issued and multiply it by Orgenesis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Orgenesis conducts business under Biotechnology sector and is part of Health Care industry. The entity has 4.77 M outstanding shares of which 56.25 K shares are now shorted by private and institutional investors with about 2.39 trading days to cover.
Orgenesis currently holds about 2.3 M in cash with (14.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09.
Check Orgenesis Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Orgenesis is $10.07 Million. Orgenesis has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Orgenesis Ownership Details
Orgenesis Risk Profiles
| Mean Deviation | 69.81 | |||
| Semi Deviation | 28.99 | |||
| Standard Deviation | 113.03 | |||
| Variance | 12776.03 |
Orgenesis Stock Against Markets
Orgenesis Pink Sheet Analysis Notes
About 21.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.26. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Orgenesis recorded a loss per share of 8.0. The entity last dividend was issued on the 16th of November 2017. The firm had 1:10 split on the 25th of September 2024. Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 151 people.The quote for Orgenesis is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Orgenesis contact Vered MSc at 480 659 6404 or learn more at https://orgenesis.com.Orgenesis Investment Alerts
| Orgenesis is way too risky over 90 days horizon | |
| Orgenesis has some characteristics of a very speculative penny stock | |
| Orgenesis appears to be risky and price may revert if volatility continues | |
| Orgenesis has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 530 K. Net Loss for the year was (64.92 M) with profit before overhead, payroll, taxes, and interest of 36.02 M. | |
| Orgenesis currently holds about 2.3 M in cash with (14.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09. | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders |
Orgenesis Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.07 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Orgenesis's market, we take the total number of its shares issued and multiply it by Orgenesis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 28th of January, Orgenesis holds the Risk Adjusted Performance of 0.1902, semi deviation of 28.99, and Coefficient Of Variation of 408.3. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Orgenesis, as well as the relationship between them. Please check Orgenesis downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Orgenesis is priced some-what accurately, providing market reflects its current price of 0.6 per share. As Orgenesis is a penny stock we also suggest to check out its total risk alpha numbers.Orgenesis Price Movement Analysis
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. Orgenesis Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Orgenesis price patterns.
Orgenesis Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Orgenesis insiders, such as employees or executives, is commonly permitted as long as it does not rely on Orgenesis' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Orgenesis insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Orgenesis Outstanding Bonds
Orgenesis issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Orgenesis uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Orgenesis bonds can be classified according to their maturity, which is the date when Orgenesis has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Orgenesis Predictive Daily Indicators
Orgenesis intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Orgenesis pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Orgenesis Forecast Models
Orgenesis' time-series forecasting models are one of many Orgenesis' pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Orgenesis' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Be your own money manager
Our tools can tell you how much better you can do entering a position in Orgenesis without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Financial Widgets Now
Financial WidgetsEasily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
| All Next | Launch Module |
Orgenesis Corporate Management
| Victor Miller | Chief Officer | Profile | |
| Osher Rheinisch | General Officer | Profile | |
| Neil CPA | S CFO | Profile | |
| Shimon Hassin | Chief Officer | Profile | |
| Efrat Kunik | Chief Officer | Profile | |
| Pierre Lammeretz | Interim Officer | Profile | |
| Evan Fishman | Chief Officer | Profile |
Additional Tools for Orgenesis Pink Sheet Analysis
When running Orgenesis' price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.